Biodexa Pharmaceticals Total Liabilities
Biodexa Pharmaceticals total liabilities. Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has total liabilities worth $6.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BDRX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Biodexa Pharmaceticals (2012–2025)
Total liabilities of Biodexa Pharmaceticals from 2012 to 2025. This chart illustrates how Biodexa Pharmaceticals's total liabilities have evolved over time, based on quarterly financial data.
Biodexa Pharmaceticals Competitors by Total Liabilities
The table below lists competitors of Biodexa Pharmaceticals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Middlefield Canadian Income PCC - Middlefield Canadian Income - GBP PC
LSE:MCT
|
UK | GBX28.28 Million |
|
Monarca Minerals Inc
V:MMN
|
Canada | CA$6.00 Million |
|
Dios Exploration Inc.
V:DOS
|
Canada | CA$131.84K |
|
Alexium International Group Limited
F:E7T
|
Germany | €3.28 Million |
|
Sodas Sodyum Sanayi AS
IS:SODSN
|
Turkey | TL9.87 Million |
|
MW Trade S.A.
WAR:MWT
|
Poland | zł3.94 Million |
|
Hedera Group publ AB
ST:HEGR
|
Sweden | Skr122.20 Million |
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
Germany | €385.21K |
Liability Composition Analysis (2012–2025)
This chart breaks down Biodexa Pharmaceticals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Biodexa Pharmaceticals's balance sheet.
Liquidity & Leverage Metrics
Biodexa Pharmaceticals Total Liabilities Ratios Explained
Biodexa Pharmaceticals total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biodexa Pharmaceticals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual total liabilities of Biodexa Pharmaceticals from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.76 Million | +4.71% |
| 2024-12-31 | $6.46 Million | +10.13% |
| 2023-12-31 | $5.86 Million | +148.16% |
| 2022-12-31 | $2.36 Million | -3.96% |
| 2021-12-31 | $2.46 Million | -20.60% |
| 2020-12-31 | $3.10 Million | -72.66% |
| 2019-12-31 | $11.34 Million | +222.07% |
| 2018-12-31 | $3.52 Million | -75.80% |
| 2017-12-31 | $14.55 Million | +32.68% |
| 2016-12-31 | $10.96 Million | -36.08% |
| 2015-12-31 | $17.15 Million | +267.01% |
| 2014-12-31 | $4.67 Million | +5.89% |
| 2013-12-31 | $4.41 Million | -62.86% |
| 2012-12-31 | $11.89 Million | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more